PROCEPT BioRobotics (NASDAQ:PRCT) Stock Price Target Raised at UBS Group

Key Points

• UBS raised its price target on PROCEPT BioRobotics from $20 to $21 but maintained a Neutral rating; the new target implies 3.6% upside from the prior close.
• Analyst sentiment remains cautious: the consensus rating is Hold, with an average price target of $25.
• Shares fell 6.4% after quarterly results missed estimates: the loss was $0.46 per share versus $0.39 expected, and revenue was $98.3 million versus $100.5 million expected. Revenue nevertheless grew 18% year over year.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) had its price objective boosted by analysts at UBS Group from $20.00 to $21.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The brokerage currently has a "neutral" rating on the stock. UBS Group's target price suggests a potential upside of 3.60% from the company's previous close.

Several other brokerages have also commented on PRCT. Jefferies Financial Group reiterated a "hold" rating and issued a $20.00 target price on shares of PROCEPT BioRobotics in a research report on Wednesday, August 5th. Wells Fargo & Company cut PROCEPT BioRobotics from an "overweight" rating to an "equal weight" rating and set a $19.00 target price on the stock. in a research report on Wednesday, August 5th. Truist Financial set a $21.00 price target on shares of PROCEPT BioRobotics in a research report on Wednesday, August 5th. Leerink Partners lifted their target price on PROCEPT BioRobotics from $20.00 to $22.00 and gave the stock a "market perform" rating in a report on Thursday. Finally, Oppenheimer restated a "market perform" rating on shares of PROCEPT BioRobotics in a research report on Wednesday, September 9th. Three equities research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, PROCEPT BioRobotics currently has a consensus rating of "Hold" and a consensus target price of $25.00.

PROCEPT BioRobotics Stock Down 6.4%

NASDAQ PRCT traded down $1.39 on Thursday, reaching $20.27. The company had a trading volume of 3,108,199 shares, compared to its average volume of 1,509,829. The firm has a market capitalization of $1.16 billion, a PE ratio of -10.45 and a beta of 0.88. The firm has a 50-day moving average of $19.34 and a 200-day moving average of $23.23. The company has a debt-to-equity ratio of 0.15, a current ratio of 6.55 and a quick ratio of 5.35. PROCEPT BioRobotics has a 1 year low of $16.67 and a 1 year high of $38.11.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The company reported ($0.46) earnings per share for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.07). PROCEPT BioRobotics had a negative net margin of 32.53% and a negative return on equity of 30.62%. The firm had revenue of $98.29 million during the quarter, compared to analysts' expectations of $100.52 million. During the same period in the previous year, the company earned ($0.38) earnings per share. The business's quarterly revenue was up 18.0% on a year-over-year basis. On average, equities research analysts anticipate that PROCEPT BioRobotics will post -1.67 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Larry Wood purchased 23,900 shares of the stock in a transaction on Friday, August 7th. The shares were bought at an average price of $20.85 per share, for a total transaction of $498,315.00. Following the completion of the acquisition, the chief executive officer directly owned 23,900 shares in the company, valued at approximately $498,315. This trade represents a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold a total of 1,043 shares of company stock worth $21,851 in the last 90 days. Company insiders own 4.00% of the company's stock.

Hedge Funds Weigh In On PROCEPT BioRobotics

Large investors have recently made changes to their positions in the business. BlackRock Inc. bought a new position in PROCEPT BioRobotics during the second quarter worth $109,961,000. Jupiter Topco LLC acquired a new stake in shares of PROCEPT BioRobotics in the 2nd quarter valued at $24,914,000. William Blair Investment Management LLC bought a new stake in PROCEPT BioRobotics during the 2nd quarter worth approximately $16,020,000. Bank of America Corp DE acquired a new stake in PROCEPT BioRobotics in the 2nd quarter valued at about $11,656,000. Finally, CPMG Inc bought a new stake in shares of PROCEPT BioRobotics during the first quarter worth $10,661,000. Institutional investors and hedge funds own 89.46% of the company's stock.

PROCEPT BioRobotics News Roundup

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Positive Sentiment: Revenue rose 18% year over year, and PROCEPT reaffirmed its 2026 financial guidance, providing a positive counterpoint to the quarterly earnings miss. Company results and guidance
• Neutral Sentiment: Leerink Partners raised its price target from $20 to $22 but kept a Market Perform rating, signaling limited near-term conviction despite the higher target. Leerink Partners ratings
• Negative Sentiment: PRCT reported a quarterly loss of $0.46 per share, wider than the $0.39 loss analysts expected and the $0.38 loss a year earlier. Revenue of $98.3 million also fell short of the roughly $100.5 million consensus. The earnings and sales misses likely weighed on the shares. Q3 results and estimates

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation is a medical technology company focused on developing and commercializing robotic solutions for the treatment of benign prostatic hyperplasia (BPH), a noncancerous enlargement of the prostate that can cause urinary symptoms. The company's technology is designed to provide a minimally invasive alternative to conventional surgical procedures.

Its primary product is the AquaBeam Robotic System, which uses image guidance, robotic assistance and a high-velocity waterjet to remove targeted prostate tissue.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.